Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction, which is characterized by muscle weakness and fatigue. Acetylcholine inhibitors (e.g., pyridostigmine) and short- and long-term immunosuppressants, such as prednisone, mycophenolate mofetil, and azathioprine, are the most prescribed agents to manage MG symptoms. However, the MG pipeline is starting to bring novel therapies with unique mechanisms of action to the market, highlighted by the FDA approval of eculizumab (Alexion / AstraZeneca’s Soliris) and efgartigimod alfa (Argenx’s Vyvgart) in 2017 and December 2021, respectively. As the MG current treatment landscape continues to evolve, this report offers insights from real-world claims data into prescribing trends in MG to help new players better understand current treatment practices in MG and to define the market niche for their emerging products.For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Alexion Pharma
Key drugs: Pyridostigmine, prednisone, azathioprine, mycophenolate mofetil, Soliris, Rituxan, intravenous immunoglobulin
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.